NF1 sirna

NF1 siRNA (Human)

Cat. Num. AAA8204968

• Gene Names: NF1; WSS; NFNS; VRNF
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: NF1; NF1 siRNA (Human); Neurofibromin; Neurofibromatosis-related protein NF-1; NF1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: NF1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 2818

• Applicable Applications for NF1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human NF1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for NF1 sirna

siRNA to inhibit NF1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4557793
• NCBI GeneID: 4763
• NCBI Accession #: NP_000258.1
• NCBI GenBank Nucleotide #: NM_000267.3
• UniProt Accession #: P21359; O00662; Q14284; Q14930; Q14931; Q9UMK3
• Molecular Weight: 318,992 Da
• NCBI Official Full Name: neurofibromin isoform 2
• NCBI Official Synonym Full Names: neurofibromin 1
• NCBI Official Symbol: NF1
• NCBI Official Synonym Symbols: WSS; NFNS; VRNF
• NCBI Protein Information: neurofibromin
• UniProt Protein Name: Neurofibromin
• Protein Family: Neurofibromin
• UniProt Gene Name: NF1
• UniProt Entry Name: NF1_HUMAN

NCBI Description

This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]

Uniprot Description

NF1: a Ras-GAP, highly expressed in developing neural cells. Possesses tumor suppressor activity, presumably by virtue of its GTPase activating domain. Neurofibromin is phosphorylated in response to EGF in CNS cells and cell lines. Defects in NF1 are the cause of type 1 neurofibromatosis (NF1), Watson syndrome, and familial spinal neurofibromatosis. NF1 is one of the most frequent autosomal dominant diseases. Four alternatively spliced isoforms have been described.

Protein type: Nucleolus; Tumor suppressor; Motility/polarity/chemotaxis; GAPs, Ras; GAPs

Chromosomal Location of Human Ortholog: 17q11.2

Cellular Component: membrane; axon; dendrite; cytoplasm; nucleolus; nucleus

Molecular Function: protein binding; phosphatidylethanolamine binding; phosphatidylcholine binding

Biological Process: negative regulation of Rac protein signal transduction; neural tube development; negative regulation of MAP kinase activity; Schwann cell development; extracellular matrix organization and biogenesis; collagen fibril organization; positive regulation of apoptosis; heart development; negative regulation of transcription factor import into nucleus; negative regulation of neuroblast proliferation; regulation of glial cell differentiation; positive regulation of adenylate cyclase activity; negative regulation of neurotransmitter secretion; skeletal muscle development; adrenal gland development; negative regulation of cell-matrix adhesion; forebrain morphogenesis; regulation of synaptic transmission, GABAergic; myelination in the peripheral nervous system; camera-type eye morphogenesis; induction of apoptosis via death domain receptors; negative regulation of fibroblast proliferation; negative regulation of endothelial cell proliferation; negative regulation of protein kinase activity; positive regulation of endothelial cell proliferation; cerebral cortex development; actin cytoskeleton organization and biogenesis; forebrain astrocyte development; metanephros development; regulation of long-term neuronal synaptic plasticity; negative regulation of osteoclast differentiation; phosphoinositide 3-kinase cascade; wound healing; regulation of cell-matrix adhesion; regulation of blood vessel endothelial cell migration; smooth muscle development; sympathetic nervous system development; positive regulation of neuron apoptosis; visual learning; negative regulation of Ras protein signal transduction; cell communication; negative regulation of cell migration; regulation of bone resorption; negative regulation of MAPKKK cascade; MAPKKK cascade; liver development; regulation of angiogenesis; peripheral nervous system development; negative regulation of oligodendrocyte differentiation; osteoblast differentiation; negative regulation of angiogenesis; pigmentation; spinal cord development; Ras protein signal transduction; negative regulation of astrocyte differentiation; response to hypoxia; artery morphogenesis; brain development; cognition

Disease: Neurofibromatosis, Familial Spinal; Watson Syndrome; Juvenile Myelomonocytic Leukemia; Neurofibromatosis, Type I; Neurofibromatosis-noonan Syndrome